I monoterapi- studiet var hyppigheden af alvorlige infektioner 3, 6 hændelser pr.
In the monotherapy study the rate of serious infections was 3.6 events per 100 patient years of exposure in the tocilizumab group and 1.5 events per 100 patient years of exposure in the MTX group.